AMERICAN SUPERCONDUCTOR CORP /DE/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AMERICAN SUPERCONDUCTOR CORP /DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Mar 31, 2017 | $900.0K | May 25, 2017 |
| FY2015 | Mar 31, 2016 | $0 | May 31, 2016 |
| FY2015 | Mar 31, 2015 | $0 | May 31, 2016 |
| FY2015 | Mar 31, 2014 | $3.70M | May 31, 2016 |
| FY2014 | Mar 31, 2013 | $3.40M | May 28, 2015 |
| FY2013 | Mar 31, 2012 | $5.20M | Jun 5, 2014 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Mar 31, 2018 | $13.50M | Jun 6, 2018 |
| FY2017 | Dec 31, 2017 | $14.93M | Jun 6, 2018 |
| FY2017 | Sep 30, 2017 | $11.05M | Jun 6, 2018 |
| FY2017 | Jun 30, 2017 | $8.92M | Jun 6, 2018 |
| FY2017 | Mar 31, 2017 | $16.20M | Jun 6, 2018 |
| FY2017 | Dec 31, 2016 | $27.15M | Jun 6, 2018 |
| FY2017 | Sep 30, 2016 | $18.51M | Jun 6, 2018 |
| FY2017 | Jun 30, 2016 | $13.35M | Jun 6, 2018 |
| FY2016 | Mar 31, 2016 | $27.52M | May 25, 2017 |
| FY2016 | Dec 31, 2015 | $25.77M | May 25, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $61.85M | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $35.28M | May 21, 2025 |
| FY2024 | Mar 31, 2023 | $8.52M | May 29, 2024 |
| FY2022 | Mar 31, 2022 | $13.49M | Jun 1, 2022 |
| FY2022 | Mar 31, 2021 | $17.45M | Jun 1, 2022 |
| FY2021 | Mar 31, 2020 | $9.45M | Jun 2, 2021 |
| FY2020 | Mar 31, 2019 | $14.02M | Jun 2, 2020 |
| FY2018 | Mar 31, 2018 | $3.80M | Jun 5, 2019 |
| FY2017 | Mar 31, 2017 | $10.84M | Jun 6, 2018 |
| FY2017 | Mar 31, 2016 | $21.98M | Jun 6, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $6.03M | May 21, 2025 |
| FY2024 | Mar 31, 2024 | ($11.11M) | May 29, 2024 |
| FY2024 | Mar 31, 2023 | ($35.04M) | May 29, 2024 |
| FY2022 | Mar 31, 2022 | ($19.19M) | Jun 1, 2022 |
| FY2022 | Mar 31, 2021 | ($22.68M) | Jun 1, 2022 |
| FY2021 | Mar 31, 2020 | ($17.10M) | Jun 2, 2021 |
| FY2020 | Mar 31, 2019 | $26.76M | Jun 2, 2020 |
| FY2017 | Mar 31, 2018 | ($6.00M) | Jun 6, 2018 |
| FY2017 | Dec 31, 2017 | ($4.25M) | Jun 6, 2018 |
| FY2017 | Sep 30, 2017 | ($7.28M) | Jun 6, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($1.08M) | May 21, 2025 |
| FY2025 | Mar 31, 2024 | ($11.37M) | May 21, 2025 |
| FY2024 | Mar 31, 2023 | ($33.01M) | May 29, 2024 |
| FY2022 | Mar 31, 2022 | ($21.09M) | Jun 1, 2022 |
| FY2022 | Mar 31, 2021 | ($23.17M) | Jun 1, 2022 |
| FY2021 | Mar 31, 2020 | ($23.13M) | Jun 2, 2021 |
| FY2020 | Mar 31, 2019 | $34.02M | Jun 2, 2020 |
| FY2017 | Mar 31, 2018 | ($5.81M) | Jun 6, 2018 |
| FY2017 | Dec 31, 2017 | ($3.85M) | Jun 6, 2018 |
| FY2017 | Sep 30, 2017 | ($7.81M) | Jun 6, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $11.43M | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $7.99M | May 21, 2025 |
| FY2024 | Mar 31, 2023 | $8.97M | May 29, 2024 |
| FY2022 | Mar 31, 2022 | $10.47M | Jun 1, 2022 |
| FY2022 | Mar 31, 2021 | $11.02M | Jun 1, 2022 |
| FY2021 | Mar 31, 2020 | $9.57M | Jun 2, 2021 |
| FY2020 | Mar 31, 2019 | $9.87M | Jun 2, 2020 |
| FY2018 | Mar 31, 2018 | $11.59M | Jun 5, 2019 |
| FY2017 | Mar 31, 2017 | $12.54M | Jun 6, 2018 |
| FY2017 | Mar 31, 2016 | $12.30M | Jun 6, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $43.09M | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $31.60M | May 21, 2025 |
| FY2024 | Mar 31, 2023 | $28.70M | May 29, 2024 |
| FY2022 | Mar 31, 2022 | $27.49M | Jun 1, 2022 |
| FY2022 | Mar 31, 2021 | $25.32M | Jun 1, 2022 |
| FY2021 | Mar 31, 2020 | $22.67M | Jun 2, 2021 |
| FY2020 | Mar 31, 2019 | $22.03M | Jun 2, 2020 |
| FY2018 | Mar 31, 2018 | $22.58M | Jun 5, 2019 |
| FY2017 | Mar 31, 2017 | $25.69M | Jun 6, 2018 |
| FY2017 | Mar 31, 2016 | $28.86M | Jun 6, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $28.29M | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $2.14M | May 21, 2025 |
| FY2024 | Mar 31, 2023 | ($22.49M) | May 29, 2024 |
| FY2022 | Mar 31, 2022 | ($18.98M) | May 31, 2023 |
| FY2021 | Mar 31, 2021 | ($8.68M) | Jun 2, 2021 |
| FY2021 | Mar 31, 2020 | ($16.50M) | Jun 2, 2021 |
| FY2020 | Mar 31, 2019 | $42.71M | Jun 2, 2020 |
| FY2018 | Mar 31, 2018 | ($24.83M) | Jun 5, 2019 |
| FY2017 | Mar 31, 2017 | ($11.22M) | Jun 6, 2018 |
| FY2017 | Mar 31, 2016 | ($4.56M) | Jun 6, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $2.42M | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $934.0K | May 21, 2025 |
| FY2024 | Mar 31, 2023 | $1.24M | May 29, 2024 |
| FY2022 | Mar 31, 2022 | $938.0K | May 31, 2023 |
| FY2021 | Mar 31, 2021 | $1.76M | Jun 2, 2021 |
| FY2021 | Mar 31, 2020 | $3.63M | Jun 2, 2021 |
| FY2020 | Mar 31, 2019 | $952.0K | Jun 2, 2020 |
| FY2018 | Mar 31, 2018 | $2.53M | Jun 5, 2019 |
| FY2017 | Mar 31, 2017 | $656.0K | Jun 6, 2018 |
| FY2017 | Mar 31, 2016 | $1.20M | Jun 6, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $310.52M | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $232.77M | May 21, 2025 |
| FY2024 | Mar 31, 2023 | $175.56M | May 29, 2024 |
| FY2022 | Mar 31, 2022 | $173.89M | May 31, 2023 |
| FY2022 | Mar 31, 2021 | $168.87M | Jun 1, 2022 |
| FY2021 | Mar 31, 2020 | $124.11M | Jun 2, 2021 |
| FY2020 | Mar 31, 2019 | $119.33M | Jun 2, 2020 |
| FY2018 | Mar 31, 2018 | $88.18M | Jun 5, 2019 |
| FY2017 | Mar 31, 2017 | $100.24M | Jun 6, 2018 |
| FY2016 | Mar 31, 2016 | $135.32M | May 25, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $113.41M | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $88.20M | May 21, 2025 |
| FY2024 | Mar 31, 2023 | $93.76M | May 29, 2024 |
| FY2022 | Mar 31, 2022 | $64.50M | May 31, 2023 |
| FY2022 | Mar 31, 2021 | $52.27M | Jun 1, 2022 |
| FY2021 | Mar 31, 2020 | $51.89M | Jun 2, 2021 |
| FY2020 | Mar 31, 2019 | $38.14M | Jun 2, 2020 |
| FY2018 | Mar 31, 2018 | $35.95M | Jun 5, 2019 |
| FY2017 | Mar 31, 2017 | $40.02M | Jun 6, 2018 |
| FY2016 | Mar 31, 2016 | $51.77M | May 25, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $197.11M | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $144.57M | May 21, 2025 |
| FY2025 | Mar 31, 2023 | $81.80M | May 21, 2025 |
| FY2024 | Mar 31, 2022 | $109.39M | May 29, 2024 |
| FY2022 | Mar 31, 2021 | $116.59M | May 31, 2023 |
| FY2022 | Mar 31, 2020 | $72.22M | Jun 1, 2022 |
| FY2021 | Mar 31, 2019 | $81.19M | Jun 2, 2021 |
| FY2020 | Mar 31, 2018 | $52.23M | Jun 2, 2020 |
| FY2018 | Mar 31, 2017 | $60.23M | Jun 5, 2019 |
| FY2017 | Mar 31, 2016 | $83.55M | Jun 6, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $48.16M | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $43.47M | May 21, 2025 |
| FY2024 | Mar 31, 2023 | $43.47M | May 29, 2024 |
| FY2022 | Mar 31, 2022 | $43.47M | May 31, 2023 |
| FY2022 | Mar 31, 2021 | $34.63M | Jun 1, 2022 |
| FY2021 | Mar 31, 2020 | $1.72M | Jun 2, 2021 |
| FY2020 | Mar 31, 2019 | $1.72M | Jun 2, 2020 |
| FY2018 | Mar 31, 2018 | $1.72M | Jun 5, 2019 |
| FY2017 | Mar 31, 2017 | $0 | Jun 6, 2018 |
| FY2011 | Mar 31, 2010 | $36.70M | Jun 6, 2012 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($1.06B) | May 21, 2025 |
| FY2025 | Mar 31, 2024 | ($1.07B) | May 21, 2025 |
| FY2024 | Mar 31, 2023 | ($1.06B) | May 29, 2024 |
| FY2022 | Mar 31, 2022 | ($1.02B) | May 31, 2023 |
| FY2022 | Mar 31, 2021 | ($1.00B) | Jun 1, 2022 |
| FY2021 | Mar 31, 2020 | ($978.64M) | Jun 2, 2021 |
| FY2020 | Mar 31, 2019 | ($961.54M) | Jun 2, 2020 |
| FY2018 | Apr 1, 2018 | ($988.37M) | Jun 5, 2019 |
| FY2018 | Mar 31, 2018 | ($988.33M) | Jun 5, 2019 |
| FY2017 | Mar 31, 2017 | ($955.56M) | Jun 6, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $79.49M | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $90.52M | May 21, 2025 |
| FY2024 | Mar 31, 2023 | $23.36M | May 29, 2024 |
| FY2022 | Mar 31, 2022 | $40.58M | May 31, 2023 |
| FY2022 | Mar 31, 2021 | $67.81M | Jun 1, 2022 |
| FY2021 | Mar 31, 2020 | $24.70M | Jun 2, 2021 |
| FY2020 | Mar 31, 2019 | $77.48M | Jun 2, 2020 |
| FY2018 | Mar 31, 2018 | $34.08M | Jun 5, 2019 |
| FY2017 | Mar 31, 2017 | $26.78M | Jun 6, 2018 |
| FY2017 | Mar 31, 2016 | $39.33M | Jun 6, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | May 21, 2025 |
| FY2024 | Mar 31, 2024 | 0 | May 29, 2024 |
| FY2024 | Mar 31, 2023 | (1) | May 29, 2024 |
| FY2022 | Mar 31, 2022 | 0 | Jun 1, 2022 |
| FY2022 | Mar 31, 2021 | 0 | Jun 1, 2022 |
| FY2021 | Mar 31, 2020 | 0 | Jun 2, 2021 |
| FY2020 | Mar 31, 2019 | 1 | Jun 2, 2020 |
| FY2017 | Mar 31, 2018 | 0 | Jun 6, 2018 |
| FY2017 | Dec 31, 2017 | 0 | Jun 6, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Jun 6, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | May 21, 2025 |
| FY2024 | Mar 31, 2024 | 0 | May 29, 2024 |
| FY2024 | Mar 31, 2023 | (1) | May 29, 2024 |
| FY2022 | Mar 31, 2022 | 0 | Jun 1, 2022 |
| FY2022 | Mar 31, 2021 | 0 | Jun 1, 2022 |
| FY2021 | Mar 31, 2020 | (1) | Jun 2, 2021 |
| FY2020 | Mar 31, 2019 | 1 | Jun 2, 2020 |
| FY2017 | Mar 31, 2018 | 0 | Jun 6, 2018 |
| FY2017 | Dec 31, 2017 | 0 | Jun 6, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Jun 6, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 39.48M | May 21, 2025 |
| FY2025 | Mar 31, 2024 | 36.95M | May 21, 2025 |
| FY2024 | Mar 31, 2023 | 29.54M | May 29, 2024 |
| FY2022 | Mar 31, 2022 | 28.52M | May 31, 2023 |
| FY2022 | Mar 31, 2021 | 27.59M | Jun 1, 2022 |
| FY2021 | Mar 31, 2020 | 22.60M | Jun 2, 2021 |
| FY2020 | Mar 31, 2019 | 21.41M | Jun 2, 2020 |
| FY2013 | Mar 31, 2014 | 78.93M | Jun 5, 2014 |
| FY2013 | Mar 31, 2013 | 60.30M | Jun 5, 2014 |
| FY2012 | Mar 31, 2012 | 51.96M | Jun 14, 2013 |